Review of regulatory recommendations for orphan drug submissions in the netherlands and scotland: Focus on the underlying pharmacoeconomic evaluations

Clinical Therapeutics

Volumn 32, Issue 9, 2010, Pages 1651-1661

  Vegter, Stefan ^a   Rozenbaum, Mark H ^a   Postema, Roelien ^a   Tolley, Keith ^b   Postma, Maarten J ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Tolley Health Economics Ltd   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness; Drug guidance; Europe; Orphan drug; Pharmacoeconomics; Reimbursement

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; BETAINE; BUSULFAN; CARGLUMIC ACID; CELECOXIB; CLOFARABINE; DEFERASIROX; ECULIZUMAB; GALSULFASE; IBUPROFEN; ICATIBANT; IDURONATE 2 SULFATASE; IMATINIB; KUVAN; LARONIDASE; LENALIDOMIDE; MITOTANE; NELARABINE; NITISINONE; OMEGA CONOTOXIN MVIIA; ORPHAN DRUG; PEGVISOMANT; RAZOXANE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RUFINAMIDE; SILDENAFIL; SORAFENIB; STIRIPENTOL; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DRUG INDICATION; NETHERLANDS; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REIMBURSEMENT; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NETHERLANDS; ORPHAN DRUG PRODUCTION; QUALITY-ADJUSTED LIFE YEARS; RARE DISEASES; REIMBURSEMENT MECHANISMS; SCOTLAND;

EID: 77958187982     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.08.006     Document Type: Article

References (17)

1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products uri=OJ:L:2000:018:0001:0005:EN:PDF. Accessed July 27, 2010. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?
2. Press release: Committee for Orphan Medicinal Products, September 2007 meeting European Medicines Agency, Accessed August 1, 2010. http://www.emea.europa.eu/pdfs/human/comp/42020707en?pdf.
3. Analysis of hospital pharmaceuticals: Country report-the Netherlands Danish Ministry of Health and Prevention, Accessed August 1, 2010. http://www.sum.dk/Aktuelt/Publikationer/~/media/Filer%20-%20Publikationer_i_pdf/2009/Landerapport%20Nederlandene%20sygehusmedicin.ashx.
4. Protocol on assessment of inpatient medication [in Dutch] Dutch Health Care Insurance Board, Accessed August 1, 2010. http://www.cvz.nl/binaries/live/CVZ_lnternet/hst_content/nl/documenten/rapporten/2006/rpt0604+intramurale+geneesmiddelen.pdf.
5. Guidelines for outcomes research [in Dutch] Dutch Health Care Insurance Board, Accessed August 1, 2010. http://www.cvz.nl/binaries/live/CVZ_lnternet/hst_content/nl/documenten/rapporten/2008/rpt0812+leidraad+uitkomstenonderzoek.pdf.
6. The role of SMC Scottish Medicines Consortium, Accessed August 1, 2010. http://www.scottishmedicines.org.uk.
7. Orphanet report series-Prevalence of rare diseases: Bibliographic data Orphanet, Accessed August 1, 2010. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf.
8. Heemstra HE, de Vrueh RL, van Weely S, et al. Orphan drug development across Europe: Bottlenecks and opportunities. Drug Discov Today. 2008, 13:670-676.
9. Levine M, Taylor R, Ryan M, Sculpher M Decisionmaking by healthcare payers. Respir Med. 2002, 96(Suppl C):S31-S38.
10. Protocol on assessment of outpatient medication [in Dutch] Dutch Health Care Insurance Board, Accessed August 1, 2010. http://www.cvz.nl/binaries/live/CVZ_Internet/hst_content/nl/documenten/rapporten/2007/rpt0707+beoordeling+extramurale+geneesmiddelen.pdf.
11. List of orphan drugs in Europe Orphanet, Accessed August 1, 2010. http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf.
12. McCabe C, Claxton K, Tsuchiya A Orphan drugs and the NHS: Should we value rarity?. BMJ. 2005, 331:1016-1019.
13. Burls A, Austin D, Moore D Commissioning for rare diseases: View from the frontline. BMJ. 2005, 331:1019-1021.
14. Gericke CA, Riesberg A, Busse R Ethical issues in funding orphan drug research and development. J Med Ethics. 2005, 31:164-168.
15. Haffner ME, Torrent-Farnell J, Maher PD Does orphan drug legislation really answer the needs of patients?. Lancet. 2008, 371:2041-2044.
16. Hughes DA, Tunnage B, Yeo ST Drugs for exceptionally rare diseases: Do they deserve special status for funding?. QJM. 2005, 98:829-836.
17. Sheehan M Orphan drugs and the NHS: Fairness in health care entails more than cost effectiveness. BMJ. 2005, 331:1144-1145.